{"entity":{"id":"nct06102057","kind":"trial","name":"PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC","aka":["PACCELIO"],"tldr":"A phase 2 trial in lung cancer, run by TheraOp, now recruiting.","summary":"PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC is a phase 2, randomised interventional study registered as NCT06102057 by TheraOp, with a registry enrolment figure of 110 participants, started 2024-07-01 and due to reach its primary completion in 2026-06. Interventions recorded: standard Radiotherapy; Chemotherapy; Immunotherapy; Experimental Radiotherapy. Conditions listed: Stage III Non-small Cell Lung Cancer; Locally Advanced; Unresectable. Primary outcome: Comparison of the Completion rate of Experimental Arm to Conventional Arm. Lung eligibility wording from the registry: \"* Patients with histologically or cytologically documented NSCLC who present with locally advanced, unresectable (Stage III) disease (according to version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology (IASLC Staging Manual in Thoracic Oncology 20\". Sites: Germany, Switzerland. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06102057","url":"https://clinicaltrials.gov/study/NCT06102057"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["stage-iii-unresectable-nsclc"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06102057","phase":"2","setting":"PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC","sponsor":"TheraOp","enrolled":110,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06102057/","neighbours":{"cancer":[{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}